Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20207664 | 0.81 | CYP1A2 (0.36) | ADORA2AIRAK4NOS1NOS2 | |
| SCHEMBL22751134 | 0.81 | IRAK4 (0.33) | CCR4IRAK4 | |
| SCHEMBL2476938 | 0.81 | KCNH2 (0.41) | CCR4MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL31481285 | 0.78 | KCNH2 (0.36) | ADORA2ANOS1NOS2CHRNA7 | |
| SCHEMBL1581851 | 0.78 | KCNH2 (0.36) | ADORA2ANOS1NOS2CHRNA7 | |
| SCHEMBL1912681 | 0.78 | MEN1 (0.47) | CCR4MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL21100036 | 0.77 | GABRA1 (0.35) | CCR4TRPV3NOS1NOS2 | |
| SCHEMBL17658978 | 0.77 | KCNH2 (0.34) | ADORA2AIRAK4TRPV3 | |
| SCHEMBL4051420 | 0.76 | CCR1 (0.40) | ADORA2ANOS1NOS2CHRNA7 | |
| SCHEMBL19363978 | 0.76 | ADORA2A (0.34) | ADORA2ANOS1NOS2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340140-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340140-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | CDK6, CDK4, CDKL4 | CCR4 2631/4885ADORA2A 3639/4885IRAK4 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.